Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib (BGB-290) in Advanced Solid Tumors
NCT02361723Phase 1Completed
- Sponsor
- BeiGene
- Start
- Jul 2014
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pamiparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 4 more (5 cohorts), sponsored by BeiGene. Primary endpoints: Objective Response Rate, Prostate-Specific Antigen Response and 1 more. Started Jul 2014; status: completed.
02
Drugs
pamiparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)breast cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT02361723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02361723.